Serological aggravation of autoimmune thyroid disease in two cases receiving nivolumab
Serological aggravation of autoimmune thyroid disease in two cases receiving nivolumab
复制标题
DOI：
10.1111/1346-8138.13028
复制
发表时间：
2016-02-01
影响因子：
3.1
通讯作者：
Kawada, Akira
中科院分区：
文献类型：
--
作者：
Narita, Tomohiko;Oiso, Naoki;Kawada, Akira
Nivolumab是一种程序性细胞死亡1的阻断剂，目前用于晚期恶性黑色素瘤。Nivolumab相关不良事件包括器官特异性自身免疫性疾病、自身免疫性甲状腺疾病、白癜风和胰岛素依赖型糖尿病。然而，目前尚不清楚易感人群。在这里，我们报告了两例接受纳武利尤单抗治疗的自身免疫性甲状腺疾病的血清学恶化：一例患有桥本病，另一例患有可能的亚临床桥本病。我们应该验证nivolumab相关的甲状腺功能减退症和甲状腺功能亢进症是否易发生在甲状腺功能正常的亚临床自身免疫性甲状腺疾病患者中。
Nivolumab, a blockade of programmed cell death 1, is now administrated for advanced malignant melanomas. Nivolumab-associated adverse events include organ-specific autoimmune disorders; autoimmune thyroid disease, vitiligo and insulin-dependent diabetes. However, predisposed persons are currently unknown. Here, we report serological aggravation of autoimmune thyroid disease in two cases receiving nivolumab: one with Hashimoto disease and another with probable subclinical Hashimoto disease. We should verify if nivolumab-related hypothyroidism and hyperthyroidism are predisposed to occur in euthyroid individuals with subclinical autoimmune thyroid disease.